COMPARISON BETWEEN CYTOLOGY & SOME BIOMARKERS FOR DETECTION BLADDER CANCER OF IRAQI PATIENTS

Abstract

Background: Bladder cancer (BC) is the 4th most frequently occurring malignancy and the 9th most common cause of death worldwide in men. The invasive and metastatic form of the cancer is the main cause of death or unfavorable prognosis for BC patients. The presence of a bladder tumor is often discovered after episodes of painless macroscopic hematuria. At initial diagnosis, the disease is non-muscle-invasive in approximately 75% of patients. In recent years, detecting aberrantly biomarkers in serum has helped in the detection noninvasive of BC. Objective: To detect bladder tumors in Iraqi patients. Methods: In this cross-sectional study, sixty cases were suspected of having bladder tumors according to the opinion of the physician and some signs and symptoms, the best sign was hematuria in urine (per diagnosis). An additional 30 healthy controls with similar age and sex were recruited as control groups, with an average age of 37_85 years.  from Baghdad Medical City / Ghazi al–Hariri Teaching Hospital and AlKindi Specialized Hospital during the period from September / 2023 to April / 2024. Using enzyme-linked immunosorbent assay compare the results with cytology. Results: Out of 60 bladder inflammations, the results of ELISA / BTA were highly significant differences (p < 0.01), and ELISA / NMP-22 were nonsignificant differences (P = 0.092). In addition. Conclusions: cytology needs some confirmative tests to detect bladder cancer.

Keywords:

bladder tumors, cytology, ELISA markers

References

SUNG, H., FERLAY, J., SIEGEL, R. L., LAVERSANNE, M., SOERJOMATARAM, I., JEMAL, A. & BRAY, F. 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 71, 209-249.

CHEN, W., ZHENG, R., ZENG, H., ZHANG, S. & HE, J. 2015. Annual report on status of cancer in China, 2011. Chinese journal of cancer research, 27, 2.

DEGERGE, K., HOLT, H. R. & HODGES, S. C. 2017. Bladder cancer: diagnosis and treatment. American Family Physician, 96, 507-514.

TABAYOYONG, W. & KAMAT, A. M. 2018. Current use and promise of urinary markers for urothelial cancer. Current urology reports, 19, 1-8.

YAFI, F. A., BRIMO, F., STEINBERG, J., APRIKIAN, A. G., TANGUAY, S. & KASSOUF, W. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urologic oncology: seminars and original investigations, 2015. Elsevier, 66. e25-66. e31.

AL-DELAIMY, W. K., AWADALLA, A., EL-ASSMY, A., ABOL-ENEIN, H. & SHOKEIR, A. 2022. Comparison of urinary telomerase, CD44, and NMP22 assays for detection of bladder squamous cell carcinoma. Current Urology, 16, 154-159.

MAAS, M., TODENHÖFER, T. & BLACK, P. C. 2023. Urine biomarkers in bladder cancer—Current status and future perspectives. Nature Reviews Urology, 20, 597-614.

JASIM MOHAMMED, B., AL-THWANI, A. N. & KANNAN, R. 2016. Demographic and genetic study for a sample of Iraqi smokers. Cancer Biology, 6, 16-27.

VAN HOOGSTRATEN, L. M., VRIELING, A., VAN DER HEIJDEN, A. G., KOGEVINAS, M., RICHTERS, A. & KIEMENEY, L. A. 2023. Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. Nature reviews Clinical oncology, 20, 287-304.

SAGINALA, K., BARSOUK, A., ALURU, J. S., RAWLA, P., PADALA, S. A. & BARSOUK, A. 2020. Epidemiology of bladder cancer. Medical sciences, 8, 15.

LENIS, A. T., LEC, P. M. & CHAMIE, K. 2020. Bladder cancer: a review. Jama, 324, 1980-1991.

CATTO, J. W., DOWNING, A., MASON, S., WRIGHT, P., ABSOLOM, K., BOTTOMLEY, S., et al. 2021. Quality of life after bladder cancer: a cross-sectional survey of patient-reported outcomes. European urology, 79, 621-632.

JABER, M., ET AL. 2017. Investigation of PCR Marker Correlations in Iraqi Cancer Patients. Iraqi Journal of Medical Sciences, 14 123 - 130.

LOBO, N., AFFERI, L., MOSCHINI, M., MOSTAFID, H., PORTEN, S., PSUTKA, S. P., et al. 2022. Epidemiology, screening, and prevention of bladder cancer. European urology oncology, 5, 628-639.

TAN, W. S., TEO, C. H., CHAN, D., ANG, K. M., HEINRICH,

M., FEBER, A., et al. 2020. Exploring patients’ experience and perception of being diagnosed with bladder cancer: a mixed‐methods approach. BJU international, 125, 669-678.

GANGOPADHYAY, K. K. & SINGH, A. K. 2023. Will lobeglitazone rival pioglitazone? A systematic review and critical appraisal. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 17, 102747.

XU, B., XING, A. & LI, S. 2022. The forgotten type 2 diabetes mellitus medicine: Rosiglitazone. Diabetology international, 13, 49-65.

GRUNBERGER, G. 2013. Will PPAR-g agonist therapy still have a role in diabetes management in 2013? Diabetes Management, 3, 41.

YKI-JÄRVINEN, H. 2005. The PROactive study: some answers, many questions. The Lancet, 366, 1241-1242.

DOMINGUEZ-VALENTIN, M., SAMPSON, J. R., SEPPÄLÄ, T. T., TEN BROEKE, S. W., PLAZZER, J.-P., NAKKEN, S., et al. 2020. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genetics in Medicine, 22, 15-25.

SILVA-FERREIRA, M., CARVALHO, J. A., SALTA, S., HENRIQUES, T. S., RODRIGUES, P. P., MONTEIRO-REIS, S., et al. 2024. Diagnostic Test Accuracy of Urinary DNA Methylation-based Biomarkers for the Detection of Primary and Recurrent Bladder Cancer: A Systematic Review and Meta-analysis. European Urology Focu